Hypoalbuminaemia and heart failure: A practical review of current evidence
European Journal of Heart Failure, Volume 27, Issue 2, Page 293-306, February 2025.Abstract Hypoalbuminaemia (serum albumin levels ≤3.5 g/dl) is associated with poor outcomes among patients with heart failure (HF). This narrative review includes original articles and reviews published over the past 20 years and retrieved from PubMed using the following search terms (or their combination): ‘heart failure’, ‘hypoalbuminaemia’, ‘heart ...
Marta Biancucci +8 more
wiley +1 more source
Journal of Arrhythmia, Volume 41, Issue 1, February 2025.Hyperpolypharmacy was significantly associated with clinical outcome in patients who underwent cardiac resynchronization therapy. Noncardiovascular (CV) polypharmacy, but not CV polypharmacy, may be related to the adverse effects of hyperpolypharmacy.
Yuma Ono +9 more
wiley +1 more source
Standard Protocols for Characterising Primary and In Vitro‐Generated Human Hepatocytes
Journal of Cellular and Molecular Medicine, Volume 29, Issue 3, February 2025.ABSTRACT Hepatocyte‐like cells (HLCs) derived from pluripotent stem cells (PSCs) or direct reprogramming are an unlimited source of human hepatocytes for biomedical applications. HLCs are used to model human diseases, develop precise drugs and establish groundbreaking regenerative cell‐based therapies.
Zahra Heydari +11 more
wiley +1 more source
Tolvaptan and its potential in the treatment of hyponatremia
Therapeutics and Clinical Risk Management, 2008 Tolvaptan is a selective arginine vasopressin (AVP) V(2) receptor blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia. Currently the orally active medication is in the final stages prior to approval by the FDA for outpatient therapy. It appears to be safe and effective at promoting aquaresis and raising
Y Howard Lien, Megan B Dixon
openaire +5 more sources
Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists [PDF]
, 2016 Background and Objectives The studies were designed to test the efficacy of two peroxisome proliferator-activated receptor γ (PPARγ) agonists in two rodent models of polycystic kidney disease (PKD).
Blazer-Yost, Bonnie L. +2 more
core +1 more source
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy [PDF]
, 2017 The global nephrology community recognises the need for a cohesive plan to address the problem of chronic kidney disease (CKD). In July, 2016, the International Society of Nephrology hosted a CKD summit of more than 85 people with diverse expertise and ...
Bonventre, J +26 more
core
The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models [PDF]
, 2015 Desmopressin (dDAVP) is a safe haemostatic agent with previously reported antitumour activity. It acts as a selective agonist for the V2 vasopressin membrane receptor (V2r) present on tumour cells and microvasculature.
Alonso, Daniel Fernando +9 more
core +1 more source
The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment [PDF]
, 2017 Tolvaptan, a selective vasopressin V2 receptor antagonist, is a new generation diuretic. Its clinical efficacy is in principle due to impaired vasopressin-regulated water reabsorption via aquaporin-2 (AQP2). Nevertheless, no direct in vitro evidence that
DI MISE, Annarita +6 more
core +1 more source
Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD) [PDF]
, 2023 The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonist, leads through aquaresis to an increase in serum sodium
Baldeweg, SE +4 more
core